A role for insulin on L-arginine transport in fetal endothelial dysfunction in hyperglycaemia

Current Vascular Pharmacology

Volumn 7, Issue 4, 2009, Pages 467-474

  Sobrevia, Luis ^a   González, Marcelo ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Diabetes; Endothelium; Glucose; Human; Hyperglycaemia; L arginine; Transport

Indexed keywords

AMINO ACID; AMINO ACID TRANSPORTER; ARGININE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MESSENGER RNA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR SP1;

BLOOD VESSEL TONE; CELL TYPE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FETUS; HORMONE ACTION; HUMAN; HUMAN CELL CULTURE; HYPERGLYCEMIA; NONHUMAN; PREGNANCY DIABETES MELLITUS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; UMBILICAL VEIN;

ARGININE; BIOLOGICAL TRANSPORT; CATIONIC AMINO ACID TRANSPORTER 1; ENDOTHELIUM, VASCULAR; FETUS; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; REACTIVE OXYGEN SPECIES; UMBILICAL VEINS;

EID: 70349668934     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109789043919     Document Type: Review

References (71)

1. Fishman AP. Endothelium: A distributed organ of diverse capabilities. Ann NY Acad Sci 1982; 401: 1-8.
2. Galley H, Webster N. Physiology of the endothelium. Br J Anaesth 2004; 93: 105-13.
3. Moncada S, Palmer RMJ, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12: 365-72.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y. A novel potent vasoconstrictor peptide produced by vascular endotelial cells. Nature 1988; 332: 411-5.
5. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci 1987; 84: 9265-9.
6. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003; 83: 183-252.
7. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-34.
8. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase geneexpression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-81.
9. Desoye G, Hauguel-de Mouzon S. The human placenta in gestational diabetes mellitus. The insulin and cytokine network. Diabetes Care 2007; 30: 120-6.
10. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, et al. Rapid stimulation of L-arginine transport by D-glucose involves p42/ 44mapk and nitric oxide in human umbilical vein endothelium. Cir Res 2003; 92: 64-72.
11. Casanello P, Sobrevia L. Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res 2002; 91: 127-34.
12. Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 1988; 94: 463-8.
13. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987; 79: 170-4.
14. Guyao W, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J 1998 336: 1-17.
15. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
16. Sobrevia L, Mann GE. Dysfunction of the nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol 1997; 82: 423-52.
17. Casanello P, Escudero C, Sobrevia L. Equilibrative Nucleoside (ENTs) and Cationic Amino acid (CATs) Transporters: implications in foetal endothelial dysfunction in human pregnancy diseases. Curr Vasc Pharmacol 2007; 5: 69-84.
18. Arancibia-Garavilla Y, Toledo F, Casanello P, Sobrevia L. Nitric oxide synthesis requires activity of the cationic and neutral amino acid transport system y+L in human umbilical vein endothelium. Exp Physiol 2003; 88: 699-710.
19. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Eur J Physiol 2003; 447: 532-42.
20. Devés R, Boyd CAR. Transporters for cationic amino acids in animal cells: Discovery, structure and function. Physiol Rev 1998; 78: 487-545.
21. Palacín M, Estévez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 1998; 78: 969-1054.
22. Hammermann R, Brunn G, Racke K. Analysis of the genomic organization of the human cationic amino acid transporters CAT-1, CAT-2 and CAT-4. Amino Acids 2001; 21: 211-9.
23. González M, Flores C, Pearson JD, Casanello P, Sobrevia L. Cell signalling-mediating insulin increase of mRNA expression for cationic amino acid transporters-1 and -2 and membrane hyperpolarization in human umbilical vein endothelial cells. Eur J Physiol 2004; 448: 383-94.
24. Vásquez R, Farías M, Lvis VJ, San MR, Vecchiola A, Casanello P, et al. D-Glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-Receptors in human umbilical vein endothelium. J Cell Physiol 2007; 212: 626-32.
25. Escudero C, Casanello P, Sobrevia L. Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from preeclampsia. Placenta 2008; 29: 816-25.
26. Vásquez G, Sanhueza F, Vásquez R, González M, San Martín R, Casanello P, et al. Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol 2004; 560: 111-22.
27. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004; 47: 1727-34.
28. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal 2006; 18: 391-9.
29. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007; 3: 853-76.
30. Rath S, Kalogeris T, Mai N, Zibari G, Alexander JS, Lefer D, et al. Insulin prevents oxidant-induced endothelial cell barrier dysfunction via nitric oxide-dependent pathway. Surgery 2006; 139: 82-91.
31. Kim F, Tysseling KA, Rice J, Gallis B, Haji L, Giachelli CM, et al. Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cells. J Mol Cell Cardiol 2005; 39: 327-34.
32. Muñoz G, San Martin R, Farias M, Cea L, Vecchiola A, Casanello P, et al. Insulin restores glucose inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. J Cell Physiol 2006; 209: 826-35.
33. San Martin R, Sobrevia L. Gestational diabetes and the adenosine/ L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 2006; 27: 1-10.
34. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52: 2795-804.
35. Yano M, Hasegawa G, Ishii M, Yamasaki M, Fukui M, Nakamura N, et al. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004; 9: 111-6.
36. Carnesecchi S, Carpentier JL, Foti M, Szanto I. Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. Exp Cell Res 2006; 312: 3413-24.
37. Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev 2007; 65: S13-S23.
38. Puebla C, Farías M, González M, Vecchiola A, Aguayo C, Krause B, et al. High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. J Cell Physiol 2008; 215: 645-56.
39. González M, Vecchiola A, Farías M, Casanello P, Sobrevia L. Insulin blockage of D-glucose-stimulation of L-arginine transport does not involves Sp1 binding to SLC7A1promoter region in human fetal endothelium. Physiol Mini-Rev 2006; 1: 28.
40. Samson S, Wong NCW. Role of Sp1 in insulin regulation of gene expression. J Mol Endocrinol 2002; 29: 265-79.
41. Banfi C, Eriksson P, Giandomenico G, Mussoni L, Sironi L, Hamsten A, et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 2001; 50: 1522-30.
42. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 1998; 273: 18959-65.
43. Lam JK, Matsubara S, Mihara K, Zheng XL, Mooradian AD, Wong NC. Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry 2003; 42: 2680-90.
44. Solomon SS, Palazzolo MR, Takahashi T, Raghow R. Transcription factor Sp1 is necessary for basal calmodulin gene transcription and for its selective stimulation by insulin. Endocrinology 1997; 138: 5052-64.
45. Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghow R, et al. Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of Sp1 and its subcellular compartmentalization in liver cells. J Biol Chem 2006; 281: 3642-50.
46. Horovitz-Fried M, Sampson SR. Involvement of PKCalpha in insulin-induced PKCdelta expression: Importance of SP-1 and NFkappaB transcription factors. Biochem Biophys Res Commun 2007; 352: 78-83.
47. Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol Life Sci 2005; 63: 144-62.
48. Grimm S, Baeuerle PA. The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. Biochem J 1993; 290: 297-308.
49. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol 2008; 294: C675-C682.
50. Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, Sugiya H. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem 2002; 238: 11-8.
51. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17: 2115-7.
52. Schaecher K, Goust JM, Banik NL. The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 2004; 29: 1443-51.
53. Chetty A, Cao GJ, Nielsen HC. Insulin-like growth factor-I signaling mechanisms, type I collagen and alpha smooth muscle actin in human fetal lung fibroblasts. Pediatr Res 2006; 60: 389-94.
54. Kühnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, et al. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 2000; 275: 6421-7.
55. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
56. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
57. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol 2005; 25: 539-45.
58. Mohan S, Hamuro M, Koyoma K, Sorescu GP, Jo H, Natarajan M. High glucose induced NF-kappaB DNA-binding activity in HAEC is maintained under low shear stress but inhibited under high shear stress: role of nitric oxide. Atherosclerosis 2003; 171: 225-34.
59. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450-63.
60. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87: 722-4.
61. Chae YM, Park KK, Magae J, Lee IS, Kim CH, Kim HC, et al. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 2004; 319: 550-5.
62. Fukuda H, Noguchi T, Iritani N. Transcriptional regulation of insulin receptor gene promoter in rat hepatocytes. Biochem Biophys Res Commun 2001; 280: 1274-8.
63. Fukuda H, Iritani N. Transcriptional regulation of leptin gene promoter in rat. FEBS Lett 1999; 455: 165-9.
64. Daniel S, Kim KH. Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter. J Biol Chem 1996; 271: 1385-92.
65. Ammendola R, Mesuraca M, Russo T, Cimino F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 1994; 225: 483-9.
66. Schäfer D, Hamm-Künzelmann B, Hermfisse U, Brand K. Differences in DNA-binding efficiency of Sp1 to aldolase and pyruvate kinase promoter correlate with altered redox states in resting and proliferating rat thymocytes. FEBS Lett 1996; 391: 35-8.
67. Xin X, Khan ZA, Chen S, Chakrabarti S. Glucose-induced Akt1 activation mediates fibronectin synthesis in endothelial cells. Diabetologia 2005; 48: 2428-36.
68. Kouroedov A, Eto M, Joch H, Volpe M, Lüscher TF, Cosentino F. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004; 110: 91-6.
69. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol 2003; 284: C263-72.
70. Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun 2003; 303: 313-9.
71. Chan EL, Murphy JT. Reactive oxygen species mediate endotoxin-induced human dermal endothelial NF-kappaB activation. J Surg Res 2003; 111: 120-6.